Vivos Therapeutics, Inc. (VVOS)
$0.331
-0.02 (-5.48%)
Rating:
Recommendation:
-
| Symbol | VVOS |
|---|---|
| Price | $0.331 |
| Beta | 2.832 |
| Volume Avg. | 2.99M |
| Market Cap | 8.279M |
| Shares () | - |
| 52 Week Range | 0.302-2.962 |
| 1y Target Est | - |
| DCF Unlevered | VVOS DCF -> | |
|---|---|---|
| DCF Levered | VVOS LDCF -> | |
| ROE | -215.11% | Strong Sell |
| ROA | -207.77% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 86.71% | Buy |
| P/E | -0.28 | Neutral |
| P/B | 0.71 | Buy |
Latest VVOS news
About
Download (Excel)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.